Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bexarotene · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Bexarotene | DRUG | - |
| Iressa | DRUG | - |
Inclusion Criteria:- Patients must have histologically or cytologically confirmed NSCLC which is stage IIIB with malignant pleural effusion or stage IV and have failed therapy with at least a standard first line chemotherapy regimen, or be intolerant of standard chemotherapy. * Patients may have no...
Top 20 of 76 competitors
Bexarotene is an investigational small molecule being studied for the treatment of lung cancer, specifically non-small cell lung cancer. It is in Phase 1 clinical development and has been evaluated in combination with another agent in a completed early-stage trial.
Bexarotene is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 1 clinical development for lung cancer.
Bexarotene is in Phase 1 clinical development for lung cancer. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug is no longer in active clinical trials.
Bexarotene has been studied in one clinical trial, identified as NCT00238628. This was a Phase 1/2 study of bexarotene in combination with ZD1839 (Iressa) for the treatment of non-small cell lung cancer. The trial was completed in the United States and enrolled 12 participants.
No, Bexarotene is not the same as ZD1839. Bexarotene is the investigational drug being studied, while ZD1839, also known as Iressa, is a separate agent used in combination with bexarotene in a clinical trial for non-small cell lung cancer.